-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Orient (605116.SH) issued an announcement. Recently, Yangzhou Orient Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an estradiol didroprogesterone tablet “Drug Registration Certificate” approved and issued by the State Drug Administration. This drug is a hormone replacement therapy (HRT) medication and is suitable for treating symptoms of oestrogen deficiency in women at least 12 months after menopause.
Share
Listen to the news
Zhitong Finance App News, Orient (605116.SH) issued an announcement. Recently, Yangzhou Orient Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received an estradiol didroprogesterone tablet “Drug Registration Certificate” approved and issued by the State Drug Administration. This drug is a hormone replacement therapy (HRT) medication and is suitable for treating symptoms of oestrogen deficiency in women at least 12 months after menopause.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending